🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Parkinson

French Parkinson's Disease Cohort - NS-PARK NCT04888364n/a1 site📍 Paris Institut National de la Santé Et de la Recherche Médicale, … Parkinson's Foundation Surveys NCT05066763n/a1 site📍 Miami Parkinson's Foundation · Tests: Non-interventional Study on Preliminary Safety and Efficacy of the ARC-IM Therapy to Alleviate Locomotor Deficits in People With Parkinson's Disease NCT06295614NA1 site📍 Lausanne Ecole Polytechnique Fédérale de Lausanne · Tests: ARC-IM System implantation A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product. NCT07629115n/a1 site📍 Seoul Innopeutics Corporation Effects of Vagal Nerve Stimulation on Leg Muscle Activity and Posture in Parkinson's Disease NCT07226284NA1 site📍 Minneapolis University of Minnesota · Tests: Vagal nerve stimulation, No intervention A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease. NCT06466525Phase 13 sites📍 Melbourne📍 Melbourne📍 Melbourne Longevity Biotech Australia Pty Ltd (subsidiary) · Tests: LBT-3627, Placebo Neurodegenerative Diseases Progression Markers (MARKERS-NDD) NCT06596746n/a1 site📍 Cassino Casa di Cura San Raffaele Cassino · Tests: Observation Observational Case Series of Patients With Parkinson's Disease (PD) Attending a Complementary Medicine Neuro-degenerative Disease (NDD) Clinic. NCT07207096n/a1 site📍 London St. Mary's University, Twickenham · Tests: complementary medicine Effects of Dual-Task Training on Upper Extremity Function in Parkinson's Disease NCT07536542NA1 site📍 Ankara Ankara University · Tests: Dual-Task Training LFP-based Parameter Prediction in DBS for Parkinson's Disease NCT07485621n/a1 site📍 Leuven Loes Laurijssen Movement Improves Brain Health and Cognition in Parkinson's Disease NCT07299279NA1 site📍 Roma Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Tests: Aerobic exercise for >_75 minutes/week of vigorous aerobic exercise or >_ 150 minutes/week of moderate aerobic ex… Investigating Neural Biomarkers for Gait in Parkinson's Patients NCT05820074n/a1 site📍 Vitznau Swiss Federal Institute of Technology · Tests: Neural Activity Recording, Movement Parameter Recording, Neuromodulation A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy NCT07804615Phase 230 sites📍 Scottsdale📍 Scottsdale📍 Murrieta Vima Therapeutics · Tests: VIM0423, VIM0423 Placebo Online Motor Control in People With Parkinson's Disease NCT04616508NA1 site📍 Newark University of Delaware · Tests: motor control assessment Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS) NCT06916507n/a19 sites📍 Allensbach📍 Heidelberg📍 Tübingen AbbVie Cerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Parkinson's Disease Tremor NCT06993571NA1 site📍 Hamburg Universitätsklinikum Hamburg-Eppendorf · Tests: Active-tACS, Sham-tACS, Unlocked-tACS Serotonin Release in Premotor and Motor PD NCT05516732n/a1 site📍 Exeter University of Exeter · Tests: Positron Emission Tomography (PET) scan using CIMBI-36 tracer, Magnetic Resonance Imaging (MRI) Scan, Positron Emission… Neurosurgical Outcome Network NCT06724029n/a27 sites📍 Bergamo📍 Brescia📍 Brescia Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Combined STN and NBM Deep Brain Stimulation for Mild Cognitive Impairment in Parkinson's Disease NCT05968703NA1 site📍 Stanford Helen M. Bronte-Stewart · Tests: Combined STN+NBM DBS Parkinson's Disease in Type 1 Gaucher Disease NCT07886879n/a1 site📍 New York Icahn School of Medicine at Mount Sinai Whole-Body Photobiomodulation for Motor and Cognitive Changes in Parkinson's Disease NCT07271927NA1 site📍 Yangsan Pusan National University Yangsan Hospital · Tests: Photobiomodulation Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disease and Alzheimer's Disease. NCT07467460n/a1 site📍 Pozzilli Neuromed IRCCS Action Observation and Motor Imagery Therapy in Parkinson's Disease NCT06154356NA1 site📍 Karaman Karamanoğlu Mehmetbey University · Tests: Action observation and motor imagery therapy for rehabilitation, Sham action observation and motor imagery therapy for … Application of Thoracic Epidural SCS for Managing FOG in Patients With Advanced Parkinson's Disease NCT06630702NA1 site📍 Hsinchu National Taiwan University Hospital · Tests: SCS electrode stimulation 1, SCS electrode stimulation 2, SCS electrode stimulation 3 Comparison of Vestibular and Dual-Task Rehabilitation in Parkinson's Disease NCT07277205NA1 site📍 Istanbul Marmara University · Tests: Vestibular Rehabilitation, Cognitive-Motor Dual Task Activities A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) NCT06345729Phase 3246 sites📍 Bakersfield📍 Beverly Hills📍 Stamford Merck Sharp & Dohme LLC · Tests: Calderasib, Placebo, Pembrolizumab Investigations of Dementia in Parkinson Disease NCT02763683n/a1 site📍 St Louis Washington University School of Medicine · Tests: PiB and VAT Imaging Core Aim 2, and Udall Project 2 Aim 2 NCT06998303NA1 site📍 Minneapolis University of Minnesota · Tests: Bipolar DBS stimulation Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers NCT05395624Phase 1, Phase 23 sites📍 San Francisco📍 Stanford📍 Jacksonville Ashvattha Therapeutics, Inc. · Tests: 18F-OP-801 Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study NCT04724941n/a1 site📍 Kiel University Hospital Schleswig-Holstein · Tests: No intervention
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy